Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.55 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.55 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.55 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.55 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.55 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.55 |
| ▸ | GRIK4 | Q16099 | 3/20 | 0.55 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259821 | 0.85 | SIRT2 (0.57) | PARP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9055483 | 0.80 | GRIN2D (0.53) | PARP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7242400 | 0.75 | PARP1 (1.00) | PARP1MAPTCYP1A2BLMLMNA | |
| SCHEMBL8904678 | 0.75 | GRIN2D (0.52) | PARP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30455197 | 0.73 | PARP1 (0.68) | PARP1MAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL4706926 | 0.73 | GRIN2D (0.68) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1135541 | 0.73 | PARP1 (0.68) | PARP1MAPTTDP1KMT2AALDH1A1 | |
| SCHEMBL11568200 | 0.73 | GRIN2D (0.56) | PARP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7491879 | 0.73 | PARP1 (0.62) | PARP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6007713 | 0.72 | TDP1 (0.52) | PARP1MAPTTSHRTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018183936-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS | THE BROAD INSTITUTE, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20100081657-A1 | QUINOXALINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081657-A1 | QUINOXALINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-01 | — | — | US | disclosed |
| US-7592340-B2 | Quinoxalines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592340-B2 | Quinoxalines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-22 | — | — | US | disclosed |
| US-4659713-A | POULTRY; INCORPORATED INTO FEED | INTERNATIONAL MINERALS & CHEMICAL CORP. (US) | 1987-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081657-A1 | QUINOXALINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP4K2, MAP3K5 | PARP1 789/4885GRIN2D 4255/4885GRIN3B 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.